For research use only. Not for therapeutic Use.
Teneligliptin (CAT: I009753) is a pharmaceutical drug used for the treatment of type 2 diabetes mellitus. It falls into the class of anti-diabetic drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors or gliptins. Teneligliptin works by inhibiting the enzyme DPP-4, which is responsible for the breakdown of incretin hormones. By inhibiting DPP-4, teneligliptin increases the levels of active incretin hormones, such as glucagon-like peptide-1 (GLP-1), leading to improved glucose control. This medication helps to lower blood sugar levels by promoting insulin release and suppressing glucagon secretion. Teneligliptin is typically used as an adjunct to diet and exercise in the management of type 2 diabetes.
| Catalog Number | I009753 |
| CAS Number | 760937-92-6 |
| Synonyms | Teneligliptin. trade name Tenelia.;((2S,4S)-4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-yl)(thiazolidin-3-yl)methanone |
| Molecular Formula | C₂₂H₃₀N6₆OS |
| Purity | ≥95% |
| Target | DPP-4 inhibitor |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| Related CAS | 906093-29-6 (HCl) |
| Overview of Clinical Research | <span style=”color:#000000;”><span style=”font-size:12px;”><span style=”font-family:arial,helvetica,sans-serif;”>Teneligliptin is a CD26 antigen inhibitor. Handok Pharmaceuticals initiated a phase I drug interaction trial for Type 2 diabetes mellitus (In volunteers) in South Korea (PO) in July 2020 (NCT04431141)</span></span></span> |
| IUPAC Name | [(2S,4S)-4-[4-(5-methyl-2-phenylpyrazol-3-yl)piperazin-1-yl]pyrrolidin-2-yl]-(1,3-thiazolidin-3-yl)methanone |
| InChI | InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1 |
| InChIKey | WGRQANOPCQRCME-PMACEKPBSA-N |
| SMILES | CC1=NN(C(=C1)N2CCN(CC2)C3CC(NC3)C(=O)N4CCSC4)C5=CC=CC=C5 |
| Reference | <br /> |
